Advertisement

Topics

EC Approves Soliris to Include Treatment of Refractory Generalized Myasthenia Gravis

06:16 EDT 21 Aug 2017 | PharmPro

European Commission grants new indication for Soliris (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG).
Contributed Author: 
Alexion Pharmaceuticals, Inc.
Topics: 

Original Article: EC Approves Soliris to Include Treatment of Refractory Generalized Myasthenia Gravis

NEXT ARTICLE

More From BioPortfolio on "EC Approves Soliris to Include Treatment of Refractory Generalized Myasthenia Gravis"

Advertisement
Quick Search
Advertisement
Advertisement